News Daily News Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE Michael O'Riordan November 24, 2025
News Conference News ESC 2025 HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients Caitlin E. Cox September 01, 2025
News Conference News ACC 2025 Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT Caitlin E. Cox March 29, 2025
News Opinion Editor's Corner ACC 2025 What’s Going to Be Hot at ACC 2025? Michael O'Riordan March 26, 2025
News Daily News New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients L.A. McKeown August 19, 2024
News Opinion Editor's Corner AHA 2023 What’s Going to Be Hot at AHA 2023 Shelley Wood November 07, 2023
News Daily News Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest Michael O'Riordan October 20, 2022
News Daily News Rivaroxaban Again Linked to More Bleeding vs Other DOACs Caitlin E. Cox October 11, 2021
News Conference News TCT 2020 Interventionalists, Including PERTs, Grapple With VTE Risks of COVID-19 Michael O'Riordan October 14, 2020
News Daily News NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin L.A. McKeown January 02, 2018
News Daily News Según una Revisión las Evidencias que Avalan la Exclusión Percutánea o Quirúrgica del AAI para la Prevención de ACV son Limitadas Todd Neale July 14, 2016
News Daily News Evidence Supporting Percutaneous or Surgical LAA Exclusion for Stroke Prevention Is Limited, Review Says Todd Neale July 14, 2016